内科理论与实践2025，Vol.20Issue(2)：126-131,6.DOI:10.16138/j.1673-6087.2025.02.05
海曲泊帕治疗实体肿瘤化疗所致血小板减少症的疗效及安全性回顾性研究
Retrospective study of efficacy and safety of hetrombopag in treatment of chemotherapy-induced thrombocytope-nia in patients with solid tumors
摘要
Abstract
Objective To evaluate efficacy and safety of hetrombopag in the treatment of chemotherapy-induced thrombocytopenia(CIT)in patients with solid tumors.Methods From September 2021 and June 2022,patients with CIT who were treated with hetrombopag from four hospitals were enrolled.The clinical efficacy of either hetrombopag monotherapy or hetrombopag combined with recombinant human thrombopoietin(rhTPO)/recombinant human interleukin(rhIL)-11 and the efficacy of different doses of hetrombopag were analyzed.The frequency of platelet transfusions and the incidence of adverse events were also analyzed.Results A total of 57 patients were included,in which 12 patients were in the monotherapy group(83.3%with Ⅰ-Ⅱ CIT)and 45 patients were in the combination group(64.5%with Ⅰ-Ⅱ CIT).The proportion of patients who received thrombopoietic therapy during the CIT period was significantly higher in the combination group compared to the monotherapy group(66.7%vs.0.0%,P<0.001).The overall responses rate was 89.5%,and responses rates at 7,14 and 21 days after treatment were 40.4%,77.2%and 87.7%,respectively.The responses rate was 91.7%in the monotherapy group and 88.9%in the combination group,which had no significant difference between the two groups(P=1.000).The median peak platelet count after treatment was significantly higher in the combination group compared to the monotherapy group(151.5×10⁹/L vs.126.0×10⁹/L,P=0.013).In the monotherapy groups,the responses rates of 2.5 mg/d and 5 mg/d were 100.0%and 85.7%,respectively.In the combination therapy groups,the responses rates of 2.5,5 and 7.5 mg/d were 71.4%,91.7%and 100.0%,respectively.The response rates had no significant differences among different doses of hetrombopag in both the monotherapy and combination therapy groups(P>0.05).After treatment,one patient need a platelet transfusion,and 4 patients in the combination group developed thrombocytosis.Conclusions Hetrombopag is effective and safe for treating CIT,in which monotherapy shows significant efficacy in mild to moderate cases,and hetrombopag combin with rhTPO or rhIL-11 is effectiveness in moderate to severe or refractory cases.However,the optimal dosage and combination regimen still need further investigation.关键词
海曲泊帕/化疗所致血小板减少症/实体肿瘤/疗效/安全性Key words
Hetrombopag/Chemotherapy-induced thrombocytopenia/Solid tumor/Efficacy/Safety分类
医药卫生引用本文复制引用
陈勇,陈子漩,武文娟,王晓庆,陈小军,李颖,汪瑞,李悦..海曲泊帕治疗实体肿瘤化疗所致血小板减少症的疗效及安全性回顾性研究[J].内科理论与实践,2025,20(2):126-131,6.基金项目
扬州市医学重点学科培育对象(肿瘤治疗学)项目(YZYXZDXK-013) （肿瘤治疗学）
扬州市科技计划项目(YZ2024077) （YZ2024077）
江苏省产学研合作项目(BY20221106) （BY20221106）
